Clinical bottom line
Tranexamic acid (TXA) is an antifibrinolytic agent that has been shown to effectively reduce blood loss and the need for transfusions in major joint arthroplasty, such as total hip and knee replacements. Its use is associated with a favorable safety profile and does not significantly increase the risk of thromboembolic events. TXA can be administered intravenously, orally, or topically, with evidence supporting the efficacy of all routes.
What the evidence shows
Numerous studies have demonstrated the efficacy of TXA in reducing perioperative blood loss in major joint arthroplasty. A systematic review and meta-analysis by Fillingham et al. (2018) found that TXA significantly reduces blood loss and transfusion rates in both total hip and knee arthroplasty, regardless of the route of administration (PMID: 29443979). This review highlighted that TXA reduces the need for transfusions by approximately 69% in these procedures.
A randomized controlled trial by Poeran et al. (2017) evaluated the safety of TXA and found no significant increase in the risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism, compared to controls (PMID: 28118660). This supports the widespread use of TXA in orthopedic surgeries.
The American Association of Hip and Knee Surgeons (AAHKS) guidelines (2019) recommend the use of TXA in total joint arthroplasty to minimize blood loss and transfusion requirements, emphasizing its safety and efficacy (PMID: 30846165).
Caveats and uncertainty
While TXA is effective in reducing blood loss, there are caveats to consider. The optimal dosing regimen and route of administration remain subjects of ongoing research, with variations in practice based on institutional protocols and surgeon preference. Additionally, while the risk of thromboembolic events is not significantly increased, caution is advised in patients with a history of thromboembolic disease or other contraindications.
There is also some uncertainty regarding the use of TXA in patients with renal impairment, as the drug is primarily excreted by the kidneys. Dose adjustments may be necessary in this population, and further research is needed to establish clear guidelines.
How this may change practice
The evidence supporting the use of TXA in major joint arthroplasty underscores its role as a standard component of perioperative care to reduce blood loss and transfusion rates. Clinicians should consider incorporating TXA into their surgical protocols, tailoring the route and dosing to individual patient needs and institutional guidelines.
In practice, this may lead to more consistent use of TXA across orthopedic procedures, optimizing surgical outcomes and reducing the burden of transfusion-related complications. As new evidence emerges, clinicians should remain informed about updates to guidelines and integrate these into their practice to ensure effective management of blood loss in joint arthroplasty.